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ABSTRACT 
Objective: Developing of novel pharmaceutical agents is an actual topic for chemotherapy. Heavy metals possess significant cytotoxic properties 
and some of them are widely introduced in medical practice, e. g. cisplatin. 
Methods: Silver salt of methenamine was suggested as prospective substance and tested was tested on black-motley cattle with bovine leukemia to 
reveal influence on haematological parameters. The preparation was applied in form of 0.5% solution in different doses and was administered as a 
single intravenous injection. Blood parameters were determined by triple haematological monitoring. Investigation of cytostatic activity was 
conducted on the leukemic cells of HUT-102 line in vitro in the concentration range of 0.03-3.0 mg/ml.  
Results: The results showed normalization of blood parameters in a dose-dependent manner after intravenous injection of methenamine silver salt. 
It was revealed a pronounced inhibitory effect of the silver-based drug on the leukemic cells both in vitro and in vivo. Control blood test one month 
after experimental therapy confirmed the stability of the achieved results. 
Conclusion: The tested drug showed a moderate cytostatic effect. Methenamine silver nitrate can be considered as prospective pharmacological 
agent. Bovine leukaemia was shown as a convenient model for the development of new treatment of blood diseases. Continuation of the work is of 
interest for both veterinary and medical pharmacotherapy. 
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Designing of novel cytostatic agents for leucosis treatment is a 
challenging task for modern pharmacology and medicine. Especially 
acute problem is a resistant form of decease [1-2]. A lot of modern 
approaches are used now for development delivery systems and 
screening of novel agents, e. g. virtual ligand screening [3-4]. Due to 
drug-resistivity, recently interest revived in the metal preparations of 
a new generation with cytostatic, antiviral and antibacterial activities 
[5-8]. Malignant and infectious diseases is a huge problem in 
veterinary practice as well, e. g. bovine leucosis causing enormous 
economic losses, and required new eradication approaches [9-10]. 
Currently, there are well-developed methods of laboratory diagnosis 
of bovine leukemia [11], but methods of treatment are not developed 
at all. Specific prophylaxis is only developed, but not introduced [12]. 
Bovine leukemia virus (BLV) is a retrovirus closely related to the 
human T-lymphotropic virus type 1 HTLV-I. Bovine leukemia virus 
(BLV) is a valuable model system for investigation of human 
lymphotropic viruses [13]. Here we considered viral bovine leukemia 
as a very convenient model for testing of promising antiviral and 
cytostatic agents for the medical practice, where leukemia is still a 
major problem [14]. The aim of this work is to study the cytostatic 
activity of stabilized solution of methenamine silver nitrate under in 
vitro and in vivo conditions. Previously, it was shown a wide range of 
anti-infective activity of methenamine silver nitrate [15].  
Investigation of antiblastic activity of methenamine silver nitrate 
was carried out on cattle with hematologically and serologically 
(radial immune-diffusion test) confirmed the diagnosis of bovine 
leukemia. All cows were black-motley breed, age 2-6 y, the weight of 
450-670 kg, the standard diet. Group of healthy cattle served as a 
control group (20 heads). All cows with bovine leucosis were 
randomly distributed in 2 experimental groups (15 animals each), 
depending on the dose of administration. The test preparation 
(methenamine silver nitrate) in 0.5% stabilized aqueous solution 
injected intravenously into the jugular vein at the dosage range of 
0.3 mg/kg (first experimental group) and 0.9 mg/kg (second 
experimental group). The rates of the experimental dosages were 
chosen based on preliminary data to determine the acute and 
chronic toxicity in small laboratory animals; i.e. the value of the 
experimental doses about 1% LD50. Blood parameters were 
determined by triple haematological monitoring (immediately 
before injection, during the week after and 1 mo after injection). 
Investigation of the drug cytostatic activity conducted on leukemic 
cells lines HUT-102 in the concentration range of 0.03-3.0 mg/ml. 
Cells were cultured in RPMI-1640 medium with 15% fetal calf serum 
according to standard procedures. After 24 h incubation, the 
percentage of viable cells was determined by flow cytometer. All 
results here are presented as mean±standard error of mean (SEM). 
Different groups of data were compared by Mann-Whitney U-test. 
Results of in vitro testing of the drug at varying concentrations (table 1) 
showed a pronounce inhibitory effect on the leukemic cells with 
dose-dependent cytopathic effect. 
 
Table 1: In vitro influence of methenamine silver nitrate on HUT 102 leukemic cells line, n=3 (mean±SEM) 
The percentage of viable cells of HUT-102 line, (%) 
0.03 mg/ml 0.3 mg/ml 3 mg/ml Control 
43±6 0 0 92±3 
 
Single intravenous administration of the experimental dose of 0.3 
mg/kg, resulted in a slight decrease in the number of white blood cells 
to 14.4±1.1 ths/µl (13.7% recession) and the absolute number of 
lymphocytes to 11.4±0.7 ths/µl (13.6% recession). Injection of single 
high dose (0.9 mg/kg) of the drug accompanied by more pronounced 
changes in the hematologic parameters, as shown in fig. 1.  
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Fig. 1: In vivo influence of stabilized solution of methenamine silver nitrate on the white blood cells of cattle with leukemia, n=15 (bars 
represent the standard errors of the mean) 
 
The drug contributes to the normalization blood parameters, 
reducing the number of white blood cells to 10.9±0.8 ths/µl and the 
absolute lymphocyte count to 8.6±0.5 ths/µl as well as the 
disappearance of leukemic cells. However, these parameters were 
different from healthy control group, where the total number of 
white blood cells was 7.7±0.6 ths/µl, the absolute number of 
lymphocytes was 5.4±0.3 ths/µl. Additional hematologic monitoring 
one month after treatment confirmed the stability of the achieved 
results of experimental therapy. 
Thus, tested silver-based drug revealed the moderate cytostatic 
effects with a tendency to normalization of the haematological 
parameters in experimental animals. It is important that bovine 
leukemia can be considered as a promising model for 
pharmacotherapy of blood malignant diseases. 
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